FinTechFunding

Immutep: Shares positive data from phase 2b AIPAC trial

Immutep Shares positive data from phase 2b AIPAC trial

  • Immutep (IMM) sees a significant increase in innate and adaptive immune response biomarkers in its phase IIb AIPAC trial
  • The trial evaluated efti combined with paclitaxel chemotherapy compared to a placebo group in 227 patients with HER2-negative/HR-positive metastatic breast cancer
  • IMM says the higher immune response in efti patients compared to placebo patients confirms efti is activating the immune system and improving overall survival
  • The company is a globally active biotechnology company that is a leader in developing LAG-3 related immunotherapeutic products
  • The company is trading 7.58 per cent higher at 35.5 cents
Previous article
Intigriti: Raises Over €21.13M in Series B Funding
Next article
Elixir Energy: Completes Tim-2 well in Mongolia
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

Spektr Strengthens Compliance Efforts with $20M Funding

Fintech startup Spektr secures $20 million for AI-driven compliance solutions.Highlights: Spektr raises $20 million to enhance its AI...
FinTech

Hacked DeFi Platform Drift Secures Funds to Repay Customers

Drift plans to relaunch with Tether support after addressing security issues.Highlights: Drift DeFi platform has secured funds after...
FinTech

Business Banking Fintech Slash Reaches Unicorn Status

The fintech startup achieves a valuation of over $1 billion.Highlights: Slash has been valued at over $1 billion.The...
FinTech

Amex Strengthens Digital Services with AI Expense Management Acquisition

American Express to acquire Hyper to enhance its business offerings.Highlights: American Express announces the acquisition of AI startup...